Expand ATOS Menu
ATOS MENU

ATOS Latest Press Releases

-- June 12, 2026 --

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds PRNewswire 5:31 PM

-- June 11, 2026 --

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds PRNewswire 8:00 AM

-- May 27, 2026 --

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial PRNewswire 8:30 AM

-- May 20, 2026 --

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy PRNewswire 4:45 PM

-- May 14, 2026 --

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer PRNewswire 8:30 AM

-- May 8, 2026 --

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update PRNewswire 8:45 AM

-- May 4, 2026 --

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome PRNewswire 8:30 AM

-- March 25, 2026 --

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update PRNewswire 5:30 PM

-- March 19, 2026 --

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology Globe Newswire 11:00 AM
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives PRNewswire 8:00 AM

-- March 12, 2026 --

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference PRNewswire 8:00 AM

-- February 11, 2026 --

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook PRNewswire 8:30 AM

-- February 5, 2026 --

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program PRNewswire 8:30 AM

-- January 21, 2026 --

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 PRNewswire 9:05 AM
Market Data Delayed 15 Minutes